FDA Approves Bempedoic Acid-Ezetimibe Combo for ASCVD, HeFH FDA Approves Bempedoic Acid-Ezetimibe Combo for ASCVD, HeFH
The pairing of two LDL-C-lowering agents called Nexlizet is indicated for use on top of statins to help adults with established ASCVD or heterozygous familial hypercholesterolemia reach their goals.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 27, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved Nexlizet (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-Cholesterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Non-Statin Drug That Lowers Cholesterol
TRENTON, N.J. (AP) — U.S. regulators on Friday approved a new type of cholesterol-lowering drug aimed at millions of people who can’t tolerate — or don’t get enough help from — widely used statin pills like Lipitor and Crestor. The Food and Drug Administration approved Esperion Therapeutics Inc.’s Nexletol for people genetically predisposed to have sky-high cholesterol and people who have heart disease and need to further lower their bad cholesterol. The daily pill is to be taken in conjunction with a healthy diet and the highest statin dose patients can handle, the FDA said. High LDL, o...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 24, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston Cholesterol Statins Source Type: news

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats.   Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods.  But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supple...
Source: Cochrane News and Events - February 5, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news

EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe
The CHMP has recommended approval of bempedoic acid (Nilemdo) and the combination of bempedoic acid/ezetimibe (Nustendi) for primary hypercholesterolemia and mixed dyslipidemia.International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 31, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

High-Intensity Lipid Lowering May Aid Very Elderly After ACS
TUESDAY, Aug. 6, 2019 -- Among patients hospitalized for acute coronary syndrome (ACS), the greatest benefit from simvastatin-ezetimibe compared with simvastatin alone to lower lipid levels was observed in those 75 years of age or older, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 6, 2019 Category: Pharmaceuticals Source Type: news

Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Bempedoic acid / ezetimibe fixed dose combination (FDC) tablet is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver Bempedoic acid / ezetimibe FDC tablet lowered LDL-C by 38% (placebo-corrected) and re... Biopharmaceuticals, Cardiology Daiichi Sankyo, bempedoic acid, ezetimibe, FDC tablet (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 31, 2019 Category: Pharmaceuticals Source Type: news

Jul 26 2019 This Week in Cardiology Jul 26 2019 This Week in Cardiology
CRT in patients with non-LBBB, ezetimibe, lifestyle diseases in the young, end of life care, and diabetes for the cardiologist are the topics John Mandrola, MD discusses in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

In Very Elderly, Intense Lipid-Lowering Worked in IMPROVE-IT In Very Elderly, Intense Lipid-Lowering Worked in IMPROVE-IT
The post-hoc analysis addresses a gap in the literature, said an expert observer: statin plus ezetimibe safely cut clinical risk in post-ACS patients aged> 75 compared with statin monotherapy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 24, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Fixed-Dose Bempedoic Acid, Ezetimibe Combo for Statin Intolerance? Fixed-Dose Bempedoic Acid, Ezetimibe Combo for Statin Intolerance?
The fixed-dose combination of the complementary drugs is'potent and convenient,'researchers conclude, with statin intolerance potentially'a very nice niche. 'Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 30, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Lipitor (atorvastatin) vs. Vytorin (simvastatin and ezetimibe)
Title: Lipitor (atorvastatin) vs. Vytorin (simvastatin and ezetimibe)Category: MedicationsCreated: 5/17/2019 12:00:00 AMLast Editorial Review: 5/17/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - May 17, 2019 Category: Cardiology Source Type: news

Lipitor (atorvastatin) vs. Zetia (ezetimibe)
Title: Lipitor (atorvastatin) vs. Zetia (ezetimibe)Category: MedicationsCreated: 5/17/2019 12:00:00 AMLast Editorial Review: 5/17/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - May 17, 2019 Category: Cardiology Source Type: news

Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
ANN ARBOR, Mich., May 05, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has accepted both New Drug Applications for bempedoic acid and the bempedoic acid / ezetimibe combination... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 5, 2019 Category: Drugs & Pharmacology Source Type: news

ezetimibe and simvastatin, Vytorin
Title: ezetimibe and simvastatin, VytorinCategory: MedicationsCreated: 1/31/2005 12:00:00 AMLast Editorial Review: 3/14/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - March 14, 2019 Category: Cardiology Source Type: news

ezetimibe (Zetia)
Title: ezetimibe (Zetia)Category: MedicationsCreated: 2/5/2003 12:00:00 AMLast Editorial Review: 3/1/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - March 1, 2019 Category: Cardiology Source Type: news

Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that redu... Biopharmaceuticals, Cardiology, Regulatory Daiichi Sankyo, Esperion Therapeutics, bempedoic acid, ezetimibe (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 28, 2019 Category: Pharmaceuticals Source Type: news

Ezetimibe cost saving for prevention of CV events in T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

Adherence and Intensity of Lipid-Lowering Therapy Influences CV Risk
MONDAY, Dec. 17, 2018 -- Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk, according to a study published online Dec. 7 in JAMA Network Open. Kamlesh Khunti, M.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2018 Category: Pharmaceuticals Source Type: news

Beyond Statins: PCSK9 Inhibitors, Ezetimibe, and Diet Beyond Statins: PCSK9 Inhibitors, Ezetimibe, and Diet
Experts from the Mayo Clinic discuss the spectrum of nonstatin therapies and when they consider using ezetimibe and PCSK9 inhibitors in their patients at high cardiovascular risk.Mayo Clinic (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Cardiology Roundtable Source Type: news

EWTOPIA75: Ezetimibe Reduced First Cardiac Events in Seniors EWTOPIA75: Ezetimibe Reduced First Cardiac Events in Seniors
Japanese patients 75 years and older benefited from this lipid-lowering therapy for the primary prevention of atherosclerotic cardiovascular events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

AHA: Zetia May Cut CV Events in Japanese Seniors
(MedPage Today) -- Results from EWTOPIA75 trial not enough to change practice, experts says (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 11, 2018 Category: Pediatrics Source Type: news

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge
Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent. (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Esperion says combo therapy lowers cholesterol level by 35 percent
Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Ezetimibe: Likely to Be Beneficial For All Ezetimibe: Likely to Be Beneficial For All
Is ezetimibe therapy equally beneficial to patients with or without diabetes mellitus? This commentary focuses on the clinical implications of the IMPROVE-IT trial.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 4, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Ezetimibe With Statin Therapy for Stroke Prevention in ACS Ezetimibe With Statin Therapy for Stroke Prevention in ACS
Can the addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduce the frequency of ischemic stroke?Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

PCSK9 Drugs Upgraded in Lipid Recs
(MedPage Today) -- PCSK9 inhibitors no longer behind ezetimibe (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 5, 2017 Category: Geriatrics Source Type: news

For Most Patients, Maximize Oral Lipid Therapy and Skip PCSK9s For Most Patients, Maximize Oral Lipid Therapy and Skip PCSK9s
A simulation study shows that for 86% of patients who require cholesterol lowering, statins and ezetimibe are sufficient, while the remaining 14% will need add-on PCSK9 inhibitors to reach target LDL levels.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Forget PCSK9 Drugs? Almost All Could Reach Target LDL With Oral Agents (CME/CE)
Debate is done (MedPage Today) -- focus on intense statin and ezetimibe use, groups argue (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 3, 2017 Category: Cardiology Source Type: news

High-fat diet leads to same intestinal inflammation as a virus
FINDINGSA new study by scientists at UCLA found that when mice eat a high-fat diet, the cells in their small intestines respond the same way they do to a viral infection, turning up production of certain immune molecules and causing inflammation throughout the body. The scientists also found that feeding the mice tomatoes containing a protein similar to that in HDL, or “good cholesterol,” along with the generic cholesterol drug Ezetimibe, reversed the inflammation.The results could lead to new types of drugs, targeting the intestinal cells, to reduce people ’s risk of heart attacks and strokes, or to trea...
Source: UCLA Newsroom: Health Sciences - June 21, 2017 Category: Universities & Medical Training Source Type: news

Sun Pharma receives USFDA nod for anti-cholesterol drug
"As per IMS, ezetimibe tablets had annual sales of approximately USD 2.7 billion in the US for the 12 months ended April 2017," it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 13, 2017 Category: Pharmaceuticals Source Type: news

Zydus Cadila gets USFDA nod for ezetimibe tablets
The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), the company said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 13, 2017 Category: Pharmaceuticals Source Type: news

Teva launches generic version of Merck cholesterol-lowering medicine
Teva Pharmaceutical Industries Ltd. said Monday it has launched a generic version of the cholesterol lowering medication Zetia. Zetia, which contains the active ingredient ezetimibe, is a prescription medicine made by Merck (NYSE: MRK) used to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe tablets are for patients who cannot control their cholesterol levels by diet a nd exercise alone. Teva said the product can be used by itself or with other… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 12, 2017 Category: Biotechnology Authors: John George Source Type: news

Teva launches generic version of Merck cholesterol-lowering medicine
Teva Pharmaceutical Industries Ltd. said Monday it has launched a generic version of the cholesterol lowering medication Zetia. Zetia, which contains the active ingredient ezetimibe, is a prescription medicine made by Merck (NYSE: MRK) used to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe tablets are for patients who cannot control their cholesterol levels by diet a nd exercise alone. Teva said the product can be used by itself or with other… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 12, 2017 Category: American Health Authors: John George Source Type: news

Generic Vytorin to Hit U.S. Market (FREE)
By the Editors Clinicians may soon be able to prescribe generic Vytorin (ezetimibe/simvastatin) … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 28, 2017 Category: Primary Care Source Type: news

Dr Reddy's launches cholesterol lowering drug in US
The company has launched Ezetimibe and Simvastatin tablets in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 27, 2017 Category: Pharmaceuticals Source Type: news

Impax Announces FDA Approval and Launch of a Generic Version of Vytorin(R) (Ezetimibe/Simvastatin Tablets)
HAYWARD, Calif., April 26, 2017 -- (Healthcare Sales & Marketing Network) -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced it has received final U.S. Food and Drug Administration (FDA) approval for a generic ... Biopharmaceuticals, Generics, FDA, Product Launch Impax Laboratories, Vytorin, ezetimibe, simvastatin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 26, 2017 Category: Pharmaceuticals Source Type: news

Vytorin (Ezetimibe and Simvastatin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 3, 2017 Category: Drugs & Pharmacology Source Type: news

CardioBreak: Heart'Hugger'; Watchman Without Warfarin; U.K. Rationing for Zetia?
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 23, 2017 Category: Psychiatry Source Type: news

Endo unit launches generic version of Merck blockbuster
An Endo International operating company this week launched the first generic version Merck ’s multibillion-dollar, cholesterol-lowering medicine Zetia. North Jersey-based Par Pharmaceuticals, which Endo (NASDAQ: ENDP) acquired last year for $8 billion, is the marketer and distributor of the product in the United States. Endo, based in Dublin, Ireland, has its U.S. headquarters in Malve rn. Endo eliminates 375 sales jobs According to data from IMS Health, U.S. sales of Zetia were about $2.6 billion… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 14, 2016 Category: American Health Authors: John George Source Type: news

India Launches First Generic of Merck's Zetia in U.S.
India's Glenmark Pharmaceuticals has launched the first and only generic version of Zetia -- Merck's cholesterol drug -- in the U.S. market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 13, 2016 Category: Pharmaceuticals Source Type: news

Glenmark launches generic version of Zetia in US market
"We have launched ezetimibe, the first and only generic version of Zetia (Merck) in the United States for the treatment of high cholesterol," (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2016 Category: Pharmaceuticals Source Type: news

Liptruzet (Ezetimibe and Atorvastatin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 9, 2016 Category: Drugs & Pharmacology Source Type: news

Zetia (Ezetimibe Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 12, 2016 Category: Drugs & Pharmacology Source Type: news

Farewell to the fasting cholesterol test?
At a recent meeting I offered a visitor lunch which she declined with obvious regret. She was hungry, and it was noon. But she was headed to her annual physical, and eating beforehand would mean returning another morning for a fasting cholesterol level. Most of us can relate to her annoyance, but thankfully this may soon be a thing of the past. Doctors have traditionally ordered cholesterol tests to be drawn after an overnight fast. But this requirement causes a significant burden on both sides of the health care equation. Most people hate to fast. Skipping meals is particularly difficult for active people, people with dia...
Source: New Harvard Health Information - June 16, 2016 Category: Consumer Health News Authors: Naomi D. L. Fisher, MD Tags: Health Heart Health Prevention Screening Tests and procedures Source Type: news

Merck posts better-than-expected profit, raises forecast
(Reuters) - Merck & Co Inc reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

New drug 'effective' for those with intolerable statin side effects
Conclusion The main results of this study relate to the lipid-lowering effects of two alternative non-statin medications. However, it highlights the muscle-related adverse effects that can occur with statins. The study is carefully designed and has many strengths, including: a washout period between drugs to remove any residual effects double-blind design throughout so people didn't know what they were taking sufficient duration for each phase of the study (10 and 24 weeks) to allow effects to develop a good sample size – the researchers calculated beforehand how many people would need to be recruited to...
Source: NHS News Feed - April 4, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news

Trial offers objective evidence of muscle-related side effects with statins
The first major clinical trial to include a blinded, placebo-controlled “statin re-challenge” in patients with a history of muscle-related side effects sheds new light on statin-associated muscle symptoms, according to new research. The trial also demonstrates that monthly self-injection of the relatively new non-statin cholesterol-lowering drug evolocumab reduces levels of low-density lipoprotein, or LDL, cholesterol to a greater extent than ezetimibe, a traditional drug used in statin-intolerant patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news

Some People Really Can't Take Statins For High Cholesterol, Scientists Prove
You can't write a story about the lifesaving benefits of the cholesterol-lowering drugs called statins without getting comments like this one, from reader Bill Hayman, on my story yesterday: I cannot take Crestor or Zetia or any form of statin drug! I can barely walk with any statin drug. My legs become painful and so weak, they feel like rubber. Several years ago, I used Lipitor and had four pancreatic attacks until I stopped the Lipitor. Or this, from reader James Leedy: People should be warned of side effects. Doctors should listen to patients . I have taken statins for several years. I had extreme muscle pains all t...
Source: Forbes.com Healthcare News - April 3, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
Data Simultaneously Presented in Late-Breaking Session at ACC.16 Repatha Compared to Ezetimibe Resulted in Significantly Greater Reduction in LDL-C THOUSAND OAKS, Calif., April 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins. The study showed that in patients with reproducible statin intolerance due to muscle-related side effects (MRSE), the use of Repatha compared to ez...
Source: Amgen News Release - April 3, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In Journal of the American Medical Association
Data Simultaneously Presented in Late-Breaking Session at ACC.16 Repatha Compared to Ezetimibe Resulted in Significantly Greater Reduction in LDL-C THOUSAND OAKS, Calif., April 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins. The study showed that in patients with reproducible statin intolerance due to muscle-related side effects (MRSE), the use of Repatha compared to ez...
Source: Amgen News Release - April 3, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news